Insulet Corp(PODD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 8:55 AM ET (Korea 9/11 21:55)
Full metrics table
| Index | S&P 500 | P/E | 26.7 | EPS (ttm) | 5.04 | Insider Own | 0.43% | Shs Outstand | 69.3M | Perf Week | -9.09% |
| Market Cap | 9.34B | Forward P/E | 17.47 | EPS next Y | 18.57% | Insider Trans | 2.38% | Shs Float | 69.1M | Perf Month | -6.92% |
| Enterprise Value | 9.75B | PEG | 0.75 | EPS next Q | 1.59 | Inst Own | 106.92% | Short Float | 5.35% | Perf Quarter | -10.64% |
| Income | 0.38B | P/S | 3.06 | EPS this Y | 30.85% | Inst Trans | 1.38% | Short Ratio | 2.27 | Perf Half Y | -43.61% |
| Sales | 3.05B | P/B | 6.57 | EPS next 5Y | 23.16% | ROA | 11.31% | Short Interest | 3.70M | Perf YTD | -52.62% |
| Book/sh | 20.51 | P/C | 17.46 | EPS past 3/5Y | 275.33% 102.14% | ROE | 26.02% | 52W High | -62.05% ($354.88) | Perf Year | -60.11% |
| Cash/sh | 7.71 | P/FCF | 31.79 | Sales past 3/5Y | 27.54% 24.53% | ROIC | 15.96% | 52W Low | 6.55% ($126.40) | Perf 3Y | -21.66% |
| Dividend Est. | - | EV/EBITDA | 15.25 | EPS Y/Y TTM | 59.39% | Gross Margin | 72.16% | Volatility(W/M) | 4.05% 3.76% | Perf 5Y | -54.56% |
| Dividend TTM | - | EV/Sales | 3.19 | Sales Y/Y TTM | 29.41% | Oper. Margin | 16.88% | ATR (14) | 5.99 | Perf 10Y | 228.17% |
| Dividend Ex-Date | - | Quick Ratio | 1.8 | EPS Q/Q | 234.76% | Profit Margin | 12.29% | RSI (14) | 34.95 | Recom | 2.04 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.45 | Sales Q/Q | 23.51% | SMA20 | -7.2% ($145.13) | Beta | 1.1 | Target Price | $169.86 |
| Payout | - | Debt/Eq | 0.67 | Earnings | 2026/8/5 | SMA50 | -12.12% ($153.25) | Rel Volume | 1.15 | Prev Close | $137.92 |
| Employees | 5400 | LT Debt/Eq | 0.65 | EPS/Sales Surpr. | 13.11% 1.82% | SMA200 | -35.04% ($207.33) | Avg Volume(3M) | 1.63M | Price | $134.68 |
| IPO | 2007/5/15 | Option/Short | Yes/Yes | Trades | 24999 | Volume | 1,865,968 | Change | -2.35% |
Company
PODD is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
This US medical device company develops and sells tubeless, disposable insulin pumps (Omnipod), a diabetes management device. Its growth is driven by recurring revenue from consumable pumps and the expanding diabetic population.
Over the past 1 year, on the lower side
62% below its 1-year high.
PODD makes money exceptionally well
16.88% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.9% this year.
Tap to view numbers
The price looks about right
Trading at 26.7 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -21.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 106.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LGHT 0.04%
NLSI 0.04%
HEAL 0.03%
BCSM 0.03%
TMED 0.02%It ranks #4 in the industry
Based on market cap of $9B.
PODD $9B PER 26.7
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is PODD?
PODD belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PODD?
The market cap of PODD is approximately $9.3B, ranking 981 within its sector.
What is the P/E ratio of PODD?
PODD has a P/E ratio of approximately 26.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PODD?
PODD has recorded a 52-week high of $354.88 and a low of $126.40.
